Abbott Laboratories 2010 Form 10-K Summary
Business context and reporting period
Abbott Laboratories is a diversified healthcare company operating through Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products segments, with additional diabetes-care and ophthalmic businesses. The filing covers the fiscal year ended December 31, 2010. International sales represented approximately 55% of consolidated net sales.
Major 2010 transactions included the acquisitions of Solvay Pharmaceuticals for approximately $6.1 billion, Piramal Healthcare Solutions for $2.2 billion, Facet Biotech for approximately $430 million and STARLIMS Technologies for approximately $100 million.
Financial performance and position
| Metric | 2010 | 2009 | Change |
|---|---|---|---|
| Net sales | $35.17 billion | $30.76 billion | +14.3% |
| Operating earnings | $6.09 billion | $6.24 billion | -2.4% |
| Net earnings | $4.63 billion | $5.75 billion | -19.5% |
| Diluted EPS | $2.96 | $3.69 | -19.8% |
| Gross margin | 58.3% | 57.1% | +120 basis points |
| Effective tax rate | 19.0% | 20.1% | Lower rate |
| Operating cash flow | $8.74 billion | $7.28 billion | +20.1% |
| Capital expenditures | $1.02 billion | $1.09 billion | Lower |
| Long-term debt | $12.52 billion | $11.27 billion | +11.2% |
| Total debt, including short-term borrowings | $18.9 billion | Not clearly provided in the filing summary | Higher, primarily acquisition-related |
| Cash and cash equivalents | $3.65 billion | $8.81 billion | Lower by $5.16 billion |
| Total assets | $59.46 billion | $52.42 billion | +13.4% |
Net earnings and EPS declined despite strong sales growth because of acquisition, integration and restructuring costs, higher amortization, acquired in-process research and development charges, healthcare reform impacts and the absence of significant 2009 one-time gains. Segment operating earnings increased to $9.65 billion from $8.32 billion, led by Pharmaceuticals and Vascular.
- Pharmaceutical Products sales were $19.89 billion, up 20.7%; operating earnings were $7.41 billion.
- Nutritional Products sales were $5.53 billion, up 4.7%; operating earnings were $777 million.
- Diagnostic Products sales were $3.79 billion, up 6.0%; operating earnings were $559 million.
- Vascular Products sales were $3.19 billion, up 18.6%; operating earnings were $910 million.
- Worldwide HUMIRA sales increased to $6.5 billion from $5.5 billion; management forecast low-teens HUMIRA sales growth in 2011.
Material changes versus the prior comparable period
- Sales growth was driven by the Solvay acquisition, unit growth, HUMIRA, Vascular Products and favorable foreign-exchange translation. Solvay contributed approximately $3.1 billion of 2010 sales.
- Operating cash flow increased by approximately $1.46 billion, while investing cash outflows rose substantially because acquisitions required $9.43 billion and Abbott deposited $1.87 billion into restricted escrow funds related to HUMIRA patent litigation.
- Cash and working capital declined materially after funding the Solvay and Piramal acquisitions. Working capital fell to $5.1 billion from $10.3 billion.
- Research and development expense rose 35.7% to $3.72 billion, reflecting acquired businesses, pipeline investment and restructuring charges.
- Gross margin improved, but healthcare reform negatively affected 2010 performance by more than $200 million; Abbott expected the impact to exceed $400 million in 2011.
- U.S. Depakote sales declined to $161 million from $331 million because of generic competition. U.S. pediatric nutrition sales were affected by the September 2010 voluntary recall of certain Similac powder formulas.
- Abbott issued $3.0 billion of long-term debt in 2010, with maturities in 2015, 2020 and 2040, and repaid or refinanced short-term borrowings.
Guidance, outlook, risks and unusual items
Management planned to expand emerging-market pharmaceuticals, integrate Solvay and Piramal, maximize HUMIRA, advance the vascular pipeline and maintain annual research and development spending at approximately 9.5% to 10% of sales. The filing does not provide a consolidated 2011 sales or earnings forecast.
- The Solvay-related restructuring plan is expected to generate total pretax charges of approximately $810 million to $970 million; $523 million was recorded in 2010.
- A January 2011 pharmaceutical restructuring plan is expected to generate approximately $295 million of pretax charges, including approximately $165 million in 2011.
- Abbott recorded $313 million of acquired in-process research and development expense in 2010 and $881 million of integration, restructuring and other costs associated with the Solvay and Piramal acquisitions, according to segment reconciliation disclosures.
- The NYU/Centocor HUMIRA patent case involved a judgment of approximately $1.67 billion plus $175 million of prejudgment interest. Abbott appealed, recorded no reserve and stated that the outcome could materially affect cash flows or results of operations. Approximately $1.87 billion was placed in escrow.
- Legal and environmental reserves were approximately $95 million, with an estimated possible loss range of $75 million to $115 million, excluding the HUMIRA patent case.
- Key continuing risks include patent expiration and generic competition, pricing and reimbursement controls, regulatory approvals and recalls, manufacturing interruptions, product liability, foreign exchange, acquisitions and integration, litigation, pension obligations and impairment of goodwill or intangible assets.
- Goodwill was $15.93 billion and net intangible assets were $12.15 billion at year-end. Estimated intangible amortization expense was approximately $1.6 billion in 2011.
- The voluntary Similac recall, the $189 million impairment of the sibutramine intangible asset, restructuring costs and acquisition-related charges were unusual 2010 items.
Most important facts for investors to verify
- Whether HUMIRA growth and the Solvay and Piramal acquisitions offset generic erosion, reimbursement pressure and healthcare reform costs.
- The final resolution and cash impact of the HUMIRA patent litigation and related escrow restrictions.
- Actual 2011 restructuring, integration, healthcare reform and acquisition-contingent payments versus disclosed estimates.
- Debt repayment requirements, including approximately $2.0 billion of long-term debt due in 2011, and the availability of $6.7 billion of unused credit facilities.
- Rebate accrual assumptions: rebates and chargebacks reduced gross sales by approximately $4.9 billion in 2010; a one-percentage-point increase in the rebate rate would reduce net sales by approximately $211 million.
- Goodwill and intangible-asset impairment exposure, particularly in Medical Optics, and the effect of approximately $1.6 billion of expected 2011 amortization.
- The filing reports effective internal control over financial reporting and unqualified audit opinions, but the 2010 acquisitions of Solvay and Piramal, representing approximately 20% of assets and 9% of sales, were excluded from management’s internal-control assessment.